# The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

# Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited.

For further information call: 800-211-2769

# The Medical Letter®

# On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 53 (Issue 1359) March 7, 2011 www.medicalletter.org

#### **IN BRIEF**

### **HPV Vaccine for Boys?**

The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine *Gardasil* (Merck). This vaccine is already FDA-approved for prevention of cervical cancer and genital warts in females 9-26 years old and for prevention of genital warts in males 9-26 years old. HPV types 6 and 11 cause about 90% of genital warts. Types 16 and 18 cause more than 70% of cervical cancer and about 80% of anal cancer.¹ *Gardasil* is highly effective in preventing infection with HPV types 6, 11, 16 and 18 in both males and females.²,³ (A second HPV vaccine, *Cervarix*, is also effective in preventing infection with types 16 and 18, but has no activity against types 6 and 11; it has not been approved for any indication in males.⁴)

Since 40% of women become infected with HPV within 16 months after initiation of sexual activity and neither vaccine prevents cancer if it is given after infection, vaccination against HPV is now recommended routinely for girls 11-12 years old. Routine vaccination of boys with *Gardasil* would benefit unvaccinated girls as well as the boys themselves.

- H De Vuyst et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626.
- A human papillomavirus vaccine. Med Lett Drugs Ther 2006; 48:65
- AR Giuliano et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364:401.
- Cervarix A second HPV vaccine. Med Lett Drugs Ther 2010; 52:37.

## The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.

EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical

School

EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D.,

Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.

CONSULTING EDITOR: Brinda M. Shah, Pharm.D.

CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine

Jules Hirsch, M.D., Rockefeller University

David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario Hans Meinertz, M.D., University Hospital, Copenhagen Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba

Jordan W. Smoller, M.D., Sc.D., Harvard Medical School

Neal H. Steigbigel, M.D., New York University School of Medicine Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University

SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Esperance A.K. Schaefer, M.D., M.P.H.,
Massachusetts General Hospital, Harvard Medical School

MANAGING EDITOR: Susie Wong

ASSISTANT MANAGING EDITOR: Liz Donohue PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

#### Subscription Services

#### Mailing Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537

### Customer Service:

Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733

Web Site: www.medicalletter.org

E-mail: custserv@medicalletter.org

#### Permissions

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

# Subscriptions (US):

1 year - \$98; 2 years - \$189; 3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.

#### E-mail site license inquiries to:

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Maior credit cards accepted.

Copyright 2011. ISSN 1523-2859